Literature DB >> 7644054

Gene transfer of wild-type p53 results in restoration of tumor-suppressor function in a medulloblastoma cell line.

M R Rosenfeld1, P Meneses, J Dalmau, M Drobnjak, C Cordon-Cardo, M G Kaplitt.   

Abstract

The replacement of functional genes into cells that lack genes or have mutant genes is the basis of gene therapy. In cancer, where cells often have multiple genetic defects, the replacement of critical genes may suffice to suppress cell growth or induce cell death. The high frequency of mutations of the p53 tumor-suppressor gene in human cancers, including primary brain tumors, suggests that p53 plays a critical role in carcinogenesis and tumor progression. We report the successful transfer of the wild-type p53 gene using a defective herpes simplex viral vector into a human medulloblastoma cell line containing a mutant copy of p53. Upon gene transfer, we detected novel expression of wild-type p53 protein in the cells. In addition, the p53 protein was functionally active, since gene transfer resulted in increased levels of mdm2 proteins and induced cell cycle arrest of the majority of transduced cells. To our knowledge, this is the first report of the use of this vector system to carry wild-type p53. We conclude that defective herpes simplex viral vectors can transfer and express p53 in human primary brain tumor cells in vitro, restoring wild-type p53 tumor-suppressor functions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7644054     DOI: 10.1212/wnl.45.8.1533

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

1.  Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.

Authors:  Annette Künkele; Katleen De Preter; Lukas Heukamp; Theresa Thor; Kristian W Pajtler; Wolfgang Hartmann; Michel Mittelbronn; Michael A Grotzer; Hedwig E Deubzer; Frank Speleman; Alexander Schramm; Angelika Eggert; Johannes H Schulte
Journal:  Neuro Oncol       Date:  2012-05-16       Impact factor: 12.300

2.  SUMO-1 enhancing the p53-induced HepG2 cell apoptosis.

Authors:  Xingrong Lu; Jilin Yi
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

Review 3.  Delivery of cell cycle genes to block astrocytoma growth.

Authors:  J Fueyo; C Gomez-Manzano; T J Liu; W K Yung
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

4.  Adeno-associated viral vector gene transfer into leptomeningeal xenografts.

Authors:  M R Rosenfeld; I Bergman; L Schramm; J A Griffin; M G Kaplitt; P I Meneses
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

5.  TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme.

Authors:  J A Kraus; M Wenghoefer; N Glesmann; S Mohr; M Beck; M C Schmidt; R Schröder; U Berweiler; W Roggendorf; S Diete; K Dietzmann; K Heuser; B Müller; R Fimmers; A von Deimling; U Schlegel
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

Review 6.  [The use of p53 as a tool for human cancer therapy].

Authors:  V P Almazov; D V Kochetkov; P M Chumakov
Journal:  Mol Biol (Mosk)       Date:  2007 Nov-Dec

Review 7.  Feasibility of herpes simplex virus type 1 mutants labeled with radionuclides for tumor treatment.

Authors:  Yan-Xia Mi; Ya-Hong Long; Yun-Chun Li
Journal:  World J Gastroenterol       Date:  2008-03-07       Impact factor: 5.742

8.  Identification of potential synthetic lethal genes to p53 using a computational biology approach.

Authors:  Xiaosheng Wang; Richard Simon
Journal:  BMC Med Genomics       Date:  2013-09-11       Impact factor: 3.063

9.  Recombinant Newcastle disease virus expressing P53 demonstrates promising antitumor efficiency in hepatoma model.

Authors:  Ying An; Tianyan Liu; Jinjiao He; Hongsong Wu; Rui Chen; Yunye Liu; Yunzhou Wu; Yin Bai; Xiaochen Guo; Qi Zheng; Chang Liu; Jiechao Yin; Deshan Li; Guiping Ren
Journal:  J Biomed Sci       Date:  2016-07-28       Impact factor: 8.410

Review 10.  Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials.

Authors:  June Kyu Hwang; JinWoo Hong; Chae-Ok Yun
Journal:  Int J Mol Sci       Date:  2020-11-16       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.